Rani Therapeutics HoldingsRANI -3.22%32 Quick Ratio is 3.40 as of Mar. 2026, which is 54% below its 10-year median of 7.43. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Rani Therapeutics Holdings ranks worse than 51.77% on this metric.
Rani Therapeutics Holdings has a quick ratio of 3.40. It generally indicates good short-term financial strength.
The historical rank and industry rank for Rani Therapeutics Holdings's Quick Ratio or its related term are showing as below:
RANI'
s Quick Ratio Range Over the Past 10 Years
Min: 0.26 Med: 7.43 Max: 45.3
Current: 3.4
During the past 7 years, Rani Therapeutics Holdings's highest Quick Ratio was 45.30. The lowest was 0.26. And the median was 7.43.
RANI's Quick Ratio is ranked worse than 51.77% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs RANI: 3.40
Rani Therapeutics Holdings (NAS:RANI) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Rani Therapeutics Holdings Quick Ratio Related Terms
Rani Therapeutics Holdings Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rani Therapeutics Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rani Therapeutics Holdings Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Rani Therapeutics Holdings's Quick Ratio falls into.
Rani Therapeutics Holdings Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rani Therapeutics Holdings (RANI) has a Quick Ratio of 3.40 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Rani Therapeutics Holdings and its competitors. This is 54% below median its historical median of 7.43. Over the past decade, Rani Therapeutics Holdings' Quick Ratio has ranged from 0.26 to 45.30. According to the industry distribution chart, Rani Therapeutics Holdings ranks #733 out of 1416 companies in the Biotechnology industry, placing it in the top 51.8%.
Is Rani Therapeutics Holdings' Quick Ratio too high?
Rani Therapeutics Holdings' current Quick Ratio of 3.40 is 54% below median its 10-year median of 7.43. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 45.30. The Biotechnology industry median Quick Ratio is 3.60. Rani Therapeutics Holdings' value of 3.40 is 5.6% below this industry median. Based on the distribution chart, Rani Therapeutics Holdings ranks #733 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' Quick Ratio compare to CGTX and INO?
According to the Biotechnology industry distribution chart, Rani Therapeutics Holdings ranks #733 out of 1416 companies for Quick Ratio. This places Rani Therapeutics Holdings in the lower half of its industry. The industry median Quick Ratio is 3.60. Rani Therapeutics Holdings' value of 3.40 is 5.6% below this benchmark. Historically, Rani Therapeutics Holdings' own Quick Ratio has ranged from 0.26 to 45.30 over the past decade. While the company's 10-year median is 7.43 vs. the industry median of 3.60, Rani Therapeutics Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rani Therapeutics Holdings's current Quick Ratio of 3.40 is 5.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Rani Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rani Therapeutics Holdings's current Quick Ratio is 3.40, which is 54% below median its own 10-year median of 7.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current Quick Ratio of 3.40. The current Quick Ratio is 3.40, which is 54% below median its 10-year median of 7.43 and 5.6% below the Biotechnology industry median of 3.60. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current Quick Ratio is 3.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score
Get the complete analysis for RANI
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RANI has been successfully added to your 
